
Treatment GuideJust DiagnosedSex & DatingAfrican AmericanStigmaAsk the HIV DocPrEP En EspañolNewsVoicesPrint IssueVideo
CONTACTCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2023 Pride Publishing Inc.
All Rights reserved
All Rights reserved
Don’t miss our latest news! Sign up today for our free newsletter.
By continuing to use our site, you agree to our Private Policy and Terms of Use.
A major study of Gardasil, an experimental human papillomavirus vaccine developed by Merck, has shown that the vaccine prevented 100% of HPV-related cervical cancer among the 10,559 women studied. None of the sexually active women who received three injections of the vaccine over six months developed cervical cancer or precancerous lesions, compared to 21 women receiving a placebo who did develop the conditions. A single dose of the vaccine was shown to be 97% effective. Cervical cancer is an AIDS-defining condition in HIV-positive women and the number 2 cause of cancer deaths among women in the United States. Merck hopes to have Gardasil on the market in 2006. A study reported in the November issue of HIV Plus showed that women with advanced HIV disease do not benefit as much from surgery to remove HPV-related cervical lesions, a precursor to cervical cancer, as women with higher CD4-cell counts; a CD4-cell count below 200 resulted in a ninefold increase in the odds of persistent or recurring intraepithelial neoplasia.
Want more breaking equality news & trending entertainment stories?
Check out our NEW 24/7 streaming service: the Advocate Channel!
Download the Advocate Channel App for your mobile phone and your favorite streaming device!
From our Sponsors
Most Popular
Don’t miss our latest news! Sign up today for our free newsletter.
Plus: Featured Video
Latest Stories
‘Kokomo City’ Gives a Searing Look Into Lives of Black Trans Sex Workers
August 18 2023 12:40 PM